The imposition of mutual rates by the American administration has added the complexity for Indian pharmaceutical companies with a considerable footprint on the American market, according to Srinivas Sadu, executive chairman of the gland pharmacy.
“These developments require strategic agility and cost discipline to guarantee continuous growth and competitiveness,” Sadu noted in his message to investors in the 2024-25 annual report.
“In the midst of these shifts, the Indian pharmaceutical sector continues to demonstrate strength and gland remains firmly positioned,” he said. He added that the basic principles of the pharmaceutical industry and the company of the gland pharma remain robust, supported by structural demand drivers and its ‘strong’ implementing options.
On the road
In the future, the most important priorities for gland pharmma would include expanding its basic company through operational excellence, market expansion, differentiated delivery platforms. The company wants to improve the production possibilities with a focus on scalability, quality and global compliance. It would also accelerate innovation by a robust pipeline of complex injectables and the upscaling of his Biologics CDMO platform, he said.
The company is also open to exploring strategic mergers and acquisitions to gain access to new technologies, to diversify its portfolio and, according to SADU, to enter unnecessary markets. “The global injectable market is expected to be witnessed by persistent expansion. This is driven by the increasing burden of chronic diseases, greater acceptance of patient -oriented formats for medicine release and progress in complex biologicians,” Sadu said.
In FY 2024-25, Gland Pharma booked consolidated sales of £ 5,616 Crore with a net profit of £ 698 Crore. In the field of regulatory front, it strengthened its worldwide compliance profile. The facilities of the gland Pharam in Dunigal and Pashamylaram in Hyderabad received Inspectorate -Inspectierparts (EIRs) from the USFDA.
“These are fundamental to maintain confidence among supervisors, customers and patients worldwide,” said Sadu.
More so
Published on August 1, 2025
#American #rates #strategic #agility #cost #discipline #guarantee #growth #gland #pharma #executive #chairman #Srinivas #Sadu